Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1FED 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma, Mantle-Cell 10Waldenstrom Macroglobulinemia 9Lymphoma, B-Cell, Marginal Zone 9Recurrence 8Lymphoma, Large B-Cell, Diffuse 8Lymphoma, Follicular 7Lymphoma, B-Cell 4Lymphoma 4B-cell Malignancies 3Lymphoma, Non-Hodgkin 2Leukemia 2Hematologic Neoplasms 2Neoplasms 1Myelodysplastic Syndromes 1Mature B-Cell Malignancies 1Lymphoma, T-Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × zanubrutinib × Clear all
NCT02569476 2024-10-26

BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies

BeiGene

Phase 1 Completed
119 enrolled 34 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma

NCT02795182 2022-07-01

Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies

BeiGene

Phase 1 Completed
75 enrolled 17 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡